Almirall, a global biopharmaceutical company focused on medical dermatology, has presented new clinical and real-world data at the 34th European Academy of Dermatology and Venereology (EADV) Congress in Paris. The company shared 44 scientific abstracts, hosted two expert-led symposia, and offered an interactive booth to support dermatologists and enhance patient care.

Real-world evidence supports lebrikizumab in atopic dermatitis

Almirall presented interim results from the ADlife study, demonstrating the effectiveness of lebrikizumab in treating moderate-to-severe atopic dermatitis. Among 100 patients treated for 16 weeks, the study showed clinically meaningful improvements in disease symptoms from as early as four weeks, with a consistent safety profile.

Long-term data from the ADjoin study reinforced sustained efficacy over two years, with continued improvements in patient-reported outcomes including itch and sleep, measured by the POEM index. The ADvantage study, using the WHO-5 Well-being Index, indicated that lebrikizumab improved psychological well-being in adults and adolescents to levels comparable with a healthy population within 16 weeks, maintained through 52 weeks.

Results from the ADvocate 1 and 2 studies further confirmed high rates of skin clearance and itch relief, with benefits observed as early as week four and maintained through one year. Almirall’s symposium on atopic dermatitis, chaired by Prof. Sébastien Barbarot, explored the role of IL-13 in disease pathophysiology and the long-term benefits of systemic biologic therapy with lebrikizumab.

New psoriasis data highlight tildrakizumab effectiveness

Real-world data from the ZODIPSO and CzATCH studies showed tildrakizumab was highly effective for moderate-to-severe plaque psoriasis, including difficult-to-treat areas such as nails, scalp, and genital regions. Additional studies addressed treatment outcomes in elderly patients, those with high disease burden, and patients with elevated body weight, while the PROCARE-t study indicated high patient and healthcare professional satisfaction.

The PRO-SCALP study demonstrated that CAL/BPD PAD cream provided significant relief of mild-to-moderate scalp psoriasis and improved emotional well-being and daily life. Almirall also hosted a symposium on unmet needs in psoriasis, chaired by Prof. Jo Lambert.

Pipeline developments in actinic keratosis and hidradenitis suppurativa

New data from the TirbAKare study confirmed tirbanibulin’s effectiveness in treating large areas of actinic keratosis, with significant lesion reduction and a favorable safety profile. Phase 1 results for LAD191, a monoclonal antibody targeting IL-1RAP in patients with hidradenitis suppurativa, indicated early clinical improvement and a positive safety profile.

Patient-centric approach at EADV 2025

Almirall’s EADV booth highlighted educational initiatives and patient support programmes, including the global “Sanctuary Salon” campaign, focusing on the emotional burden of skin conditions and promoting self-care.

Dr. Volker Koscielny, chief medical officer of Almirall, said: “Our presence at EADV reflects our commitment to advancing skin science and improving patient outcomes. We aim to provide dermatologists with meaningful insights to support patient care, based on both clinical data and real-world evidence.”